Cetuximab  -- one of the drugs Cordain mentions is another name for 
Erbitux.  Now maybe the drugs have been improved -- but below is a link to 
a 2002 Townsend Letter article which details the early disappointing 
failure of EGF blocking drugs in actual patients.  I think this EGF thing 
may be a big red herring that will translate into big bucks for big pharma -
- sounds great on paper and works in a petri dish -- but fails with respect 
to actual tumors in actual patients... Thoughts?  One particularly 
interesting quote:

"So, while on Saturday oncologists were applauding Dr. Mendelsohn for his 
brilliant insights, on Monday they were hearing that a treatment based on 
these insights simply did not work. If it were true that EGF "plays a 
critical role in the process that regulates tumor cell growth and 
survival," as ImClone still claims on its website, then one would expect a 
treatment that targets EGF to yield significant clinical results. It 
doesn't."


http://findarticles.com/p/articles/mi_m0ISW/is_2002_August-Sept/ai_90794440